Perspective Therapeutics

Perspective Therapeutics Net Margin

The Net Profit Margin of Perspective Therapeutics (CATX) as of Oct 21, 2026 is -11,665.27 %. In the previous year, Net Profit Margin was -5,452.48 % — a change of 113.94% (lower).

Net Margin

-11,665.27 %

YoY

113.94%

Last updated:

Net Profit Margin of Perspective Therapeutics is 2025 -11,665.27 % . Net Profit Margin of Perspective Therapeutics was 2024 -5,452.48 % . It decreases by 113.94% lower compared to the previous year.

Perspective Therapeutics's net margin stands at -11,665.3%, down from -31.7% several years earlier.

The Perspective Therapeutics Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
-113.12 USD
Jan 1, 2019
-66.31 USD
Jan 1, 2020
-33.77 USD
Jan 1, 2021
-31.71 USD
Jan 1, 2022
-66.26 USD
Jan 1, 2023
-206.50 USD
Jan 1, 2024
-5,452.48 USD
Jan 1, 2025
-11,665.27 USD
The Perspective Therapeutics Net Margin history
YEARNet MarginYoY
-11,665.27 %+113.94%
-5,452.48 %+2,540.38%
-206.50 %+211.65%
-66.26 %+108.95%
-31.71 %-6.10%
-33.77 %-49.07%
-66.31 %-41.38%
-113.12 %-12.60%
-129.43 %+31.03%
-98.77 %+23.61%
-79.91 %-43.42%
-141.24 %+16,472.70%
-0.85 %+23.87%
-0.69 %+26.82%
-0.54 %-28.91%
-0.76 %-32.89%
-1.14 %-4.87%
-1.20 %-28.59%
-1.67 %-59.38%
-4.12 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Perspective Therapeutics Stock analysis

What does Perspective Therapeutics do? Perspective Therapeutics Inc is a biotechnology company based in Seattle, United States, specializing in radiopharmaceutical development. The firm employs 163 people and focuses on advanced cancer treatments using proprietary technology that leverages the alpha-emitting isotope 212Pb. This approach delivers targeted radiation to cancer cells via specialized peptides, aiming to maximize efficacy while minimizing toxicity. Additionally, the company develops imaging diagnostics to personalize patient care. Its pipeline includes programs for metastatic melanoma and neuroendocrine tumors, which have entered Phase I/IIa clinical trials at academic institutions. Perspective Therapeutics also produces a 212Pb generator to secure essential isotopes for its clinical activities. The company has been listed on the market since May 31, 2002. Perspective Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Perspective Therapeutics stock

Net Profit Margin of Perspective Therapeutics is -11,665.27 % in 2025.

Net Profit Margin of Perspective Therapeutics changed from -5,452.48 % to -11,665.27 %, representing a 113.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Perspective Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Perspective Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Perspective Therapeutics

All Key Metrics — Perspective Therapeutics